Stopping Disease in its Tracks with Precision Monocyte Targeting
New Biology. Broad potential. Patients First.
clinical-Stage company developing therapies for I&I Diseases
New Adhesion Checkpoint Discovered
Potential for Highly Prevalent and Rare Inflammatory Indications
New Adhesion Checkpoint Discovered
We are focused on development of novel therapies for patients with immune inflammatory indications. Our main program is based on the discovery of a novel adhesion checkpoint, that controls the ability of certain immune cells to reach inflamed tissues.
Our Monocyte Targeting Technology
Potential for Highly Prevalent and Rare Inflammatory Indications
New Adhesion Checkpoint Discovered
Our lead clinical-stage candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from traveling to inflammatory tissues. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
Potential for Highly Prevalent and Rare Inflammatory Indications
Potential for Highly Prevalent and Rare Inflammatory Indications
Potential for Highly Prevalent and Rare Inflammatory Indications
Following demonstration of disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non-Alcoholic Steatohepatitis, IW-601 is currently being studied in the POINTGUARD clinical trial, with multiple catalysts expected in 2024-2025.
Meet Our Management
Copyright © 2024 ImmuneWalk Therapeutics - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.